Germline TP53 mutations and Li-Fraumeni syndrome

Human Mutation

Volumn 21, Issue 3, 2003, Pages 313-320

  Varley, J M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

ACC; Adrenocortical carcinoma; Cancer; Germline; Germline mutation; LFL; LFS; Li Fraumeni syndrome; Mutation detection; p53; TP53; Tumor

Indexed keywords

PROTEIN P53;

CORRELATION ANALYSIS; FAMILIAL CANCER; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GERM LINE; HUMAN; NUCLEOTIDE SEQUENCE; PEDIGREE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

FAMILY HEALTH; GENOTYPE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; PHENOTYPE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037222381     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.10185     Document Type: Review

References (71)

1. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. 1999. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531.
2. Béroud C, Soussi T. 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176-181.
3. Birch JM, Hartley AL, Marsden HB, Harris M, Swindell R. 1984. Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 49:325-331.
4. Birch JM, Hartley AL, Blair V, Kelsey AH, Harris M, Teare MD, Morris Jones PH. 1990. Cancer in the families of children with soft tissue sarcomas. Cancer 66:2237-2248.
5. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF. 1994a. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298-1304.
6. Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP, Santibanez-Koref ME 1994b. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 70:1176-1181.
7. Birch JM, Blair V, Kelsey AM, Evans DGR, Harris M, Tricker KJ, Varley JM. 1998. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17:1061-1068.
8. Birch JM, Alston RD, McNally RJQ, Evans DGR, Kelsey AM, Harris M, Eden OB, Varley JM. 2001. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621-4628.
9. Børresen A-L, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D, Friend SH. 1992. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234-3236.
10. Bougeard G, Limacher J-M, Martin C, Charbonnier F, Killian A, Delattre O, Longy M, Jonveaux P, Fricker J-P, Stoppa-Lyonnet D, Flaman J-M, Frebourg T. 2001. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and hCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 38:253-256.
11. 1 arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations. Br J Cancer 79:1657-1664.
12. Brown LT, Sexsmith E, Malkin D. 2000. Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing. Cancer Genet Cytogenet 123:65-68.
13. Burt EC, McGown G, Thorncroft M, James LA, Birch JM, Varley JM. 1999. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Br J Cancer 80:9-10.
14. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ. 1996. DNA sequence analysis of exons 2 though 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981.
15. Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA. 1995. Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet 82: 106-115.
16. Chompret A. 2002. The Li-Fraumeni syndrome. Biochimie 84:75-82.
17. Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-White ET, Martuza R, Jenkins R, Yandell D, Seizinger BR. 1991. TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chrom Cancer 3:323-331.
18. Davison TS, Yin P, Nie E, Kay C, Arrowsmith CH. 1998. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 17:651-656.
19. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. 2002. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9:12-16.
20. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. 1995. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95:1606-1611.
21. Evans DGR, Birch JM, Thorncroft M, McGown G, Lalloo F, Varley JM. 2002. Low rate of TP53 germline mutations in breast/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet (in press).
22. Felix CA, Slavc I, Dunn M, Strauss EA, Phillips PC, Rorke LB, Sutton L, Bunin GR, Biegel JA. 1995. p53 gene mutations in pediatric brain tumors. Med Pediat Oncol 25:431-436.
23. Frebourg T, Abel A, Bonaiti-Pellie C, Brugieres L, Berthet P, Bressac-de Paillerets B, Chevrier A, Chompret A, Cohen- Haguenauer O, Delattre O, Feingold J, Feunteun J, Frappaz D, Fricker JP, Gesta P, Jonveaux P, Kalifa C, Lasset C, Leheup B, Limacher JM, Longy M, Nogues C, Oppenheim D, Sommelet D, Soubrier F, Stoll C, Stoppa-Lyonnet D, Tristant H. 2001. Li-Fraumeni syndrome: update, new data and guidelines for clinical management. Bull Cancer 88: 581-587.
24. Hartley AL, Birch JM, Tricker K, Wallace SA, Kelsey AM, Harris M, Morris Jones PH. 1993. Wilms' tumor in the Li-Fraumeni cancer family syndrome. Cancer Genet Cytogenet 67:133-135.
25. Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP. 1998. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90:606-611.
26. Iavarone A, Matthay KK, Steinkirchner TM, Israel MA. 1992. Germ-line and somatic p53 mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci USA 89:4207-4209.
27. Kleihues P, Schäuble B, zur Hausen A, Estève J, Ohgaki H. 1997. Tumors associated with p53 germline mutations. A synopsis of 91 families. Am J Pathol 150:1-13.
28. Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA, Saya H. 1994. Germline p53 mutations in subsets of glioma patients. J Natl Cancer Inst 86:344-349.
29. Lalloo F, Varley J, Ellis D, O'Dair L, Pharoah P, The Early Onset Breast Cancer Study Group, Evans DGR. 2002. Family history is predictive of pathogenic, high penetrance mutations in BRCA1, BRCA2 and TP53 in early-onset breast cancer. Lancet (in press).
30. Lee SB, Kim SH, Bell DW, Wahrer DCR, Schiripo TA, Jorczak MM, Sgroi D, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KE, Harlow E, Haber DA. 2001. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 61:8062-8067.
31. Li FP, Fraumeni JE 1969a. Soft-tissue sarcomas, breast cancer and other neoplasms: a familial syndrome? Ann Intern Med 71:747-752.
32. Li FP, Fraumeni JF. 1969b. Rhabdomyosarcoma in children; epidemiologic study and identification of a cancer family syndrome. J Natl Cancer Inst 43:1365-1373.
33. Li FP, Fraumeni JF. 1982. Prospective study of a cancer family syndrome. JAMA 247:2692-2694.
34. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362.
35. Li Y-J, Sanson M, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G, Hamelin R. 1995. Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer 64:383-387.
36. Limacher J-M, Frebourg T, Natarajan-Ame S, Bergerat J-P. 2001. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96: 238-242.
37. Lomax ME, Barnes DM, Gilchrist R, Picksley SM, Varley JM, Camplejohn RS. 1997. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene 14:1869-1874.
38. Lynch HT, Krush AJ, Harlan WL, Sharp EA. 1973. Association of soft tissue sarcoma, leukemia, and brain tumors in families affected with breast cancer. Am Surg 39:199-206.
39. Lynch HT, Mulcahy GM, Harris RE, Guirgis HA, Lynch JE 1978. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer 41:2055-2064.
40. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
41. McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen A-L, Yan YX, Russo C, Sato J, Barbier N, Miser J, Malkin D, Gebhardt MC. 1994. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12:925-930.
42. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR. 2002. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:3-4.
43. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP. 2001. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Preven 10:83-91.
44. Nutting C, Camplejohn RS, Gilchrist R, Tait D, Blake P, Knee G, Yao WQ, Ross G, Fisher C, Eeles R. 2001. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol 12: 300-304.
45. Porter DE, Holden ST, Steel CM, Cohen BB, Wallace MR, Reid R. 1992. A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. J Bone Joint Surg 74:883-886.
46. Portwine C, Lees J, Verselis S, Li FP, Malkin D. 2000. Absence of germline p16(INK4a) alterations in p53 wild type Li-Fraumeni syndrome families. J Med Genet 37:E11.
47. Prosser J, Porter D, Coles C, Condie A, Thompson AM, Chetty U, Steel CM, Evans HJ. 1992. Constitutional p53 mutation in a non-Li-Fraumeni cancer family. Br J Cancer 65: 527-528.
48. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R. 2001. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98:9330-9335.
49. Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa-Ha K, Hirata Y, Mizoguchi H, Sugimura T, Terada M, Yokota J. 1992. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by screening patients with childhood adrenocortical carcinoma. J Natl Cancer Inst 84:703-707.
50. Sandrini R, Ribeiro RC, DeLacerda L. 1997. Childhood adrenocortical tumors. J Clin Endocrinol Metab 82:2027-2031.
51. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N. 1992. Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984-2986.
52. Soussi T, Caron de Fromentel C, May P. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952.
53. Soussi T, Dehouche K, Beroud C. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between carcinogenesis and epidemiology. Hum Mutat 15:105-113.
54. Soussi T, Beroud C. 2002. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:1-8.
55. Stone JG, Eeles RA, Sodha N, Murday V, Sheriden E, Houlston RS. 1999. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10. Cancer Lett 147:181-185.
56. Strong LC, Stine M, Norsted TL. 1987. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79:1213-1220.
57. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum RR, Yandell DW. 1992. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. New Engl J Med 326:1301-1308.
58. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H. 2001. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61:5718-5722.
59. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi O-P, Nevanlinna H. 2002. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432-438.
60. Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Houlston RS, Martin J, Birch JM, Evans DGR. 1995. An extended Li Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 32:946-950.
61. Varley JM, McGown G, Thorncroft M, Cochrane S, Morrison P, Woll P, Kelsey AM, Mitchell ELD, Boyle J, Birch JM, Evans DGR. 1996a. A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene 12:2437-2442.
62. Varley JM, Thorncroft M, McGown G, Tricker K, Birch JM, Evans DGR. 1996b. A novel deletion within exon 6 of TP53 in a family with Li Fraumeni-like syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genet Cytogenet 90:14-16.
63. Varley JM, Evans DGR, Birch JM. 1997a. Li-Fraumeni syndrome: a molecular and clinical review. Br J Cancer 76:1-14.
64. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DGR, Birch JM. 1997b. Germline mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245-3252.
65. Varley JM, Chapman P, McGown G, Thorncroft M, White GRM, Greaves MJ, Scott D, Spreadborough A, Tricker KJ, Birch JM, Evans DGR, Reddel R, Camplejohn RS, Burn J, Boyle JM. 1998a. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family. Oncogene 16:3291-3298.
66. Varley JM, McGown G, Thorncroft M, White GRM, Tricker KJ, Birch JM, Evans DGR. 1998b. A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: a patient with Wilms' tumour is not a mutation carrier. Br J Cancer 78:1081-1083.
67. Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DGR, Harris M, Kelsey AM, Birch JM. 1999. Are there low penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65: 995-1006.
68. Varley JM, Attwooll C, White G, McGown G, Thorncroft M, Kelsey AM, Greaves M, Boyle J, Birch JM. 2001. Characterisation of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 20: 2647-2654.
69. Varley JM. 2003. TP53, hChk2 and the Li-Fraumeni syndrome. In: El-Deiry WS, editor. Tumor suppressor genes. Volume 1. Pathways and isolation strategies. Totowa: Humana Press (in press).
70. Wagner J, Portwine C, Rabin K, Leclerc J-M, Narod SA, Malkin D. 1994. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86:1707-1710.
71. Zhou X-P, Sanson M, Hoang-Xuan K, Robin E, Taillander L, Comu P, Delattre J-Y, Thomas G, Hamelin R. 1999. Germline mutations of p53 but not p16/CDKN2 or PTEN/ MMAC1 tumor suppressor genes predispose to gliomas. Ann Neurol 46:913-916.